Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, van Diessen JNA, Sonke JJ, de Ruysscher D. Cooke SA, et al. Among authors: fredberg persson g. Radiother Oncol. 2024 Apr 24;196:110312. doi: 10.1016/j.radonc.2024.110312. Online ahead of print. Radiother Oncol. 2024. PMID: 38663582
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
Cooke SA, de Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, Lewensohn R, van Diessen JNA, Sikorska K, Lalezari F, Vogel W, van Elmpt W, Damen EMF, Sonke JJ, Belderbos JSA. Cooke SA, et al. Among authors: fredberg persson g. Radiother Oncol. 2023 Apr;181:109492. doi: 10.1016/j.radonc.2023.109492. Epub 2023 Jan 24. Radiother Oncol. 2023. PMID: 36706958 Clinical Trial.
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J. van Diessen J, et al. Among authors: fredberg persson g. Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13. Radiother Oncol. 2019. PMID: 30327236 Clinical Trial.
Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer.
Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Irming Jølck R, Larsen KR, Clementsen P, Lars Andersen T, Poulsen PR, Fredberg Persson G, Munck Af Rosenschold P. Scherman Rydhög J, et al. Among authors: fredberg persson g. Radiother Oncol. 2017 Apr;123(1):78-84. doi: 10.1016/j.radonc.2017.02.003. Epub 2017 Feb 27. Radiother Oncol. 2017. PMID: 28245908
Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer.
Scherman Rydhög J, Perrin R, Jølck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck Af Rosenschold P. Scherman Rydhög J, et al. Among authors: fredberg persson g. Radiother Oncol. 2017 Mar;122(3):393-399. doi: 10.1016/j.radonc.2016.12.027. Epub 2017 Jan 16. Radiother Oncol. 2017. PMID: 28104299